Intra-cellular Therapies, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Intra-Cellular Therapies files an amendment to its 2024 annual report to include previously omitted information on directors, executive compensation, and corporate governance, amidst an ongoing merger agreement with Johnson & Johnson.
Intra-Cellular Therapies (ITCI) has entered into a definitive agreement to be acquired by Johnson & Johnson for $132 per share in cash, valuing the company at approximately $14.6 billion.
10-K: Intra-Cellular Therapies, Inc. Details Share Structure and Corporate Governance in 10-K Filing
Intra-Cellular Therapies, Inc. outlines its common stock structure, anti-takeover provisions, and corporate governance policies in its latest 10-K filing.